Hypertension

Obesity-focused Organizations Issue Statement in Support of New AAP Clinical Guideline on Childhood Obesity

Retrieved on: 
Friday, January 13, 2023

On Jan. 9, 2023, AAP published its first clinical practice guideline on the treatment of childhood obesity, replacing recommendations last made in 2007.

Key Points: 
  • On Jan. 9, 2023, AAP published its first clinical practice guideline on the treatment of childhood obesity, replacing recommendations last made in 2007.
  • TOS and OAC support the evidence-based view of obesity presented in the guideline.
  • The Obesity Society's Pediatric Obesity Treatment Task Force emphasizes that pediatric obesity is a disease.
  • The Obesity Action Coalition (OAC) is a national nonprofit organization dedicated to elevating and empowering individuals affected by obesity through education, advocacy and support.

EQS-News: APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill

Retrieved on: 
Thursday, February 2, 2023

APONTIS PHARMA AG (ticker APPH / ISIN DE000A3CMGM5 ), a leading pharmaceutical company specializing in Single Pills in the German market, has in-licensed a new Single Pill at short notice and is thus pursuing systematically the growth strategy of the Single Pill portfolio.

Key Points: 
  • APONTIS PHARMA AG (ticker APPH / ISIN DE000A3CMGM5 ), a leading pharmaceutical company specializing in Single Pills in the German market, has in-licensed a new Single Pill at short notice and is thus pursuing systematically the growth strategy of the Single Pill portfolio.
  • The market launch of this Single Pill for the treatment of hypertension and hyperlipidemia in Germany is planned for the middle of the current financial year.
  • The new Single Pill is the first of three in-licensings that APONTIS PHARMA has planned for the current year.
  • Karlheinz Gast, Chief Executive Officer of APONTIS PHARMA AG: "The short-term in-licensing of a new Single Pill underscores our attractiveness for cooperation partners and our possibilities to steadily expand the pipeline of our Single Pill portfolio.

CinCor Pharma to be Acquired by AstraZeneca

Retrieved on: 
Monday, January 9, 2023

WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.

Key Points: 
  • WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.
  • Marc de Garidel, Chief Executive Officer at CinCor, said: “We are excited about the proposed acquisition of CinCor Pharma by AstraZeneca as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved.
  • CinCor is committed to ensuring a smooth transition of the development responsibilities to AstraZeneca once the acquisition is consummated.
  • CinCor stockholders holding approximately 44.8% of CinCor common stock have entered into a tender and support agreement with AstraZeneca, pursuant to which such stockholders have agreed, among other things, to tender 100% of their shares of CinCor common stock in the tender offer, subject to the terms and conditions of such agreement.

RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales

Retrieved on: 
Monday, January 9, 2023

BRIDGEWATER, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced preliminary fourth quarter and full year 2022 net product sales of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only U.S. Food and Drug Administration (“FDA”)-approved ophthalmic solution for blepharoptosis, or droopy eyelids, of approximately $12.1 million and $36.5 million, respectively. The preliminary fourth quarter 2022 net product sales of UPNEEQ represent a sequential increase of 21% from the third quarter 2022. The Company also announced that from February through year-end 2022 it had received orders from approximately 4,300 cumulative unique medical aesthetics practices.

Key Points: 
  • The preliminary fourth quarter 2022 net product sales of UPNEEQ represent a sequential increase of 21% from the third quarter 2022.
  • “We are proud of our progress in the fourth quarter, notably the continued upward trajectory of net product sales for UPNEEQ.
  • On a full-year basis, we expect our UPNEEQ revenues to exceed $36 million, representing nearly 400% growth over 2021.
  • The financial and operating data for the fourth quarter of 2022 and for the full year 2022 is preliminary and may change.

Global Controlled Release Drug Delivery Market Research Report 2022: Drug Dosage Analysis, Price and Clinical Trial Insights to 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The "Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Trial Insight 2028" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Trial Insight 2028" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The search for innovative solutions to the problems associated with the delivery of drugs ended with the arrival of the controlled-release drug market in the pharmaceutical sector.
  • In the past few years, the novel and mechanistic approach followed by the controlled release drugs in the treatment regimen has brought great appreciation in the pharmaceutical industry.
  • The efforts involved in the development of the market and associated parameters have helped the market to deliver promising results, thus, making the controlled release mechanism one of the widely accepted and appreciated drug delivery systems.

Vida Health Makes Two Additions to Executive Leadership Team

Retrieved on: 
Monday, January 9, 2023

Virtual cardiometabolic care leader Vida Health today announced the additions of Elaine Divelbliss and Andrew Webb to its executive leadership team.

Key Points: 
  • Virtual cardiometabolic care leader Vida Health today announced the additions of Elaine Divelbliss and Andrew Webb to its executive leadership team.
  • View the full release here: https://www.businesswire.com/news/home/20230109005207/en/
    Elaine Divelbliss and Andrew Webb join Vida Health’s executive leadership team as Chief People Officer & General Counsel and Chief Financial Officer respectively.
  • (Photo: Business Wire)
    “We’re thrilled to have Elaine and Andrew bring their wealth of knowledge and experience to Vida’s leadership team,” said Vida Health Founder and CEO Stephanie Tilenius.
  • “Stephanie and the Vida team have built an amazing product that leads to truly life-changing outcomes for its members.

Verustat Announces Clinical Study Results for RPM

Retrieved on: 
Monday, January 9, 2023

Verustat , a full-service remote care management company, today announced promising clinical results showing the ability of Verustat’s Remote Patient Monitoring (RPM) to lower blood pressure.

Key Points: 
  • Verustat , a full-service remote care management company, today announced promising clinical results showing the ability of Verustat’s Remote Patient Monitoring (RPM) to lower blood pressure.
  • New research published online in Telemedicine and e-Health shows a significant reduction in mean arterial pressure (MAP) for hypertensive patients using the Verustat RPM program.
  • Additional findings in a separate, unpublished study: In the first 3 months on the program, Verustat RPM patients with a Charlson comorbidity index >2 were compared to a matched control group who were not using RPM.
  • The patients on the Verustat RPM program showed:
    - A 29% reduction in ER visits and a 16% reduction in hospitalizations.

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

Retrieved on: 
Tuesday, January 10, 2023

Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • In Study 1, 15% of LEQEMBI-treated patients, compared to 6% of placebo-treated patients, stopped study treatment because of an adverse reaction.

ModifyHealth Secures $10 Million Series B Investment to Fuel Growing Demand for Its Medically Tailored Meals and Food as Medicine Platform

Retrieved on: 
Tuesday, January 10, 2023

ATLANTA, Jan. 10, 2023 /PRNewswire/ -- ModifyHealth™ a nationwide food as medicine platform and provider of medically tailored meals announced the closing of a $10 million Series B funding led by RC Capital (RCC) with participation from existing investor Nashville Capital Network (NCN). The partnership with RCC will support ModifyHealth's continued growth of its category-leading food as medicine solutions and further expansion of its nationwide operations to deliver meaningful patient outcomes.

Key Points: 
  • Investment supports ModifyHealth's continued growth and capability expansion to change lives by making food as medicine simple, effective, and enjoyable.
  • ATLANTA, Jan. 10, 2023 /PRNewswire/ -- ModifyHealth ™ a nationwide food as medicine platform and provider of medically tailored meals announced the closing of a $10 million Series B funding led by RC Capital (RCC) with participation from existing investor Nashville Capital Network (NCN).
  • Diet-related chronic conditions continue to rise, accounting for nearly 75% of all health care dollars spent in the US.
  • ModifyHealth's turnkey FIT™ program includes medically tailored meals, dietitian coaching, and ongoing support make adopting a healthier diet simple, achievable, and sustainable.